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body weight less or equal to 100 kg who received 45 mg. Additionally, PASI responses 
from ACCEPT between ustekinumab and etanercept were used. Costs in the model 
included drug acquisition costs only. RESULTS: In the weight-based efﬁcacy analysis, 
ustekinumab 45 mg treatment had the highest PASI 75 response. Under a ﬁxed budget 
of TL 1,000,000, it is possible to treat more patients successfully (achieving a PASI75) 
with ustekinumab 45 mg than with etanercept 50 mg biweekly. In both the ﬁrst year 
of therapy and in the maintenance year, ustekinumab 45 mg is more cost-effective 
compared to etanercept 50 mg biweekly. CONCLUSIONS: According to the results 
of the cost per responder model, ustekinumab 45 mg is more cost-effective than 
etanercept 50 mg biweekly and therefore a preferable alternative in the treatment of 
moderate to severe plaque psoriasis in Turkey.
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OBJECTIVES: To estimate the cost/efﬁcacy ratios of biologics authorized in Spain in 
2009 (adalimumab, etanercept, inﬂiximab and ustekinumab) in the management of 
moderate-severe psoriasis. METHODS: A model for economic evaluation (decision 
tree) was built for the treatments according to the available scientiﬁc evidence. The 
payer perspective (National Health System) was used, only considering drug cost and 
assuming zero cost for placebo. In the case of weight-dependent dosing, the weight of 
the study participants was adjusted by age and sex to the standard Spanish population 
corrected by the weight increment in individuals with psoriasis. The Psoriasis Area 
Severity Index (PASI) 75 criterion (improvement of 75% from baseline PASI) was used 
as indicator of efﬁcacy. The incremental efﬁcacy (calculated as the proportion of 
patients responding with PASI 75 criterion in the biologic group minus the proportion 
who respond in the placebo group) was assigned according to the outcomes of clinical 
trials at the period of time deﬁned in the primary efﬁcacy outcome. When more than 
one trial was available per treatment, a meta-analysis was undertaken (DerSimonian-
Laird method). Uncertainty was tested by deterministic sensitivity analysis, building 
scenarios with the conﬁdence intervals at 95% for costs and efﬁcacy. RESULTS: The 
incremental efﬁcacy in the baseline scenario ranged from 31.19 % (etanercept: 25 mg 
twice a week at 12 weeks of treatment) to 78.35% (inﬂiximab: 5 mg/Kg at 24 weeks 
of treatment). The efﬁciency in terms of cost/efﬁcay, in the baseline scenario, ranged 
from 38,013 (adalimumab at 16 weeks) and 317,981 (ustekinumab: 90 mg at 12 
weeks) per PASI 75 responder. In the sensitivity analysis, adalimumab remains as the 
most efﬁcient biologic on the most and least favourable scenarios. CONCLUSIONS: 
Of the biologic agents authorized in Spain for treating moderate-severe psoriasis, the 
most efﬁcient in terms of cost/efﬁcacy is adalimumab.
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OBJECTIVES: To compare the cost per responder of ustekinumab (UST) versus 
etanercept (ETN) based on head-to-head data from the ACCEPT trial, which demon-
strated greater efﬁcacy of two doses of UST, 45 mg and 90 mg at weeks 0 and 4, 
versus ETN, 50 mg twice weekly through week 12, in patients with moderate-to-
severe plaque psoriasis (PsO). METHODS: Efﬁcacy results (proportion of patients 
achieving at least 75% improvement in the Psoriasis Area and Severity Index [PASI75]) 
were obtained from the ACCEPT trial (n = 903). Given the unique dosing of UST 
(weeks 0, 4, 16, and q12 weeks thereafter), we determined the cost per PASI75 
response at week 16, the appropriate decision point for determining whether to 
proceed with a third dose. Week 16 PASI75 results were assumed to be equal to week 
12 efﬁcacy from ACCEPT; previously published randomized controlled trials have 
reported similar observations for both drugs. Dosing through week 12 was per 
ACCEPT. Dosing for weeks 13–16 was assumed to be per labeled indication in PsO. 
US wholesale acquisition cost (WAC) was used for calculating costs. The analyses used 
weight-based efﬁcacy results for UST (45 mg ≤100 kg and 90 mg >100 kg) and overall 
efﬁcacy for ETN to align with the respective approved labels for each drug. RESULTS: 
In ACCEPT, 209 patients received UST 45 mg, 347 received UST 90 mg, and 347 
received ETN. Baseline demographics and disease characteristics were comparable 
between groups. Twenty-eight percent of patients were >100 kg. The PASI75 
responses at week 12 were 72% for UST 45 mg in patients ≤100 kg and 65% for 
UST 90 mg in patients >100 kg, compared with 57% for the ETN group. At week 
16, the WAC per PASI75 response was $17,009 for UST-treated patients and $19,140 
for ETN-treated patients. CONCLUSIONS: WAC per PASI75 response was lower for 
UST relative to ETN through 16 weeks in PsO patients.
PSS11
COST-UTILITY ANALYSIS OF MAINTENANCE TREATMENT WITH 
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OBJECTIVES: A twice weekly maintenance treatment strategy with tacrolimus oint-
ment for atopic dermatitis signiﬁcantly delayed and reduced the number of disease 
ﬂares over a 12-month period compared with the standard reactive tacrolimus treat-
ment strategy. The aim of this post hoc analysis was to evaluate the cost-effectiveness 
of the maintenance strategy versus the reactive strategy in adults and children with 
moderate and severe atopic dermatitis (AD). METHODS: The evaluation was per-
formed using a decision analytic model based on the results of two pivotal phase III 
trials that were conducted in adults and children receiving 0.1% and 0.03% tacrolimus 
ointment, respectively. Clinical data were taken from the clinical trials and utility data 
were derived from a published source. The time horizon was 12 months; costs and 
utilities were applied to the treatment period and to any remaining days in the 
12-month period post-tacrolimus discontinuation. Sensitivity analyses assessed the 
degree of uncertainty around the results. The analysis was conducted from the perspec-
tive of the UK National Health Service. RESULTS: In the base-case analysis for both 
adults and children with moderate and severe AD, the maintenance treatment strategy 
with tacrolimus ointment was dominant over the reactive treatment strategy in that 
it was more effective and less costly. In univariate sensitivity analyses, for all patient 
groups, few parameters when varied between the value of their upper and lower 
conﬁdence interval resulted in incremental cost-effectiveness ratios (ICERs) above 
zero. Probabilistic sensitivity analyses demonstrated that the probability of tacrolimus 
maintenance treatment being dominant over the reactive treatment strategy was; 76% 
for adults with moderate AD, 89% for adults with severe AD, 75% for children with 
moderate AD and 54% for children with severe AD. CONCLUSIONS: Maintenance 
use of tacrolimus ointment is a dominant treatment strategy compared with reactive 
use, providing incremental health beneﬁts at a lower cost.
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OBJECTIVES: To determine cost-effectiveness of Ustekinumab in patients with mod-
erate-to-severe plaque psoriasis in comparison with Etanercept from third-party payer 
perspective. METHODS: A cost-utility analysis was performed using a Markov model 
which compared cost per QALY of Ustekinumab (45 mg at week 0 and 4, then every 
12 weeks thereafter) and Etanercept (50 mg twice weekly for the ﬁrst 12 weeks and 
then once a week). The probabilities of treatment response were taken from the 
ACCEPT trial (which compared both the drugs); while utility values for different 
stages were obtained from published studies. A 12 week paradigm for the base case 
of each agent was developed on the basis of dosage administration, laboratory moni-
toring utilized in the Randomized Clinical Trials and manufacturer’s published guide-
lines. The cost of therapies included 2009 AWP (average wholesale price) of both the 
drugs, and cost of physician visits and lab were inﬂated to 2009 from 2006 Medicare 
clinical laboratory fee schedule and physician reimbursement schedule (which used 
mean US reimbursement). Since the time frame of the analysis was only 12 weeks, the 
costs of long-term side effects and adverse events were not included. Extrapolations 
were made to evaluate the cost-effectiveness of two drugs over a period of ﬁve years, 
with costs and beneﬁts discounted at 3.5% per annum. Various sensitivity analysis 
were carried out to test the robustness of the model. RESULTS: The QALYs gained 
by Ustekinumab in comparison to Etanercept over a period of 5 years were 0.23, at 
an incremental cost-effectiveness ratio (ICER) of $65,693.59 per QALY gained.
Further sensitivity analysis conﬁrmed the robustness of results. CONCLUSIONS: 
Although as per the present analysis, Ustekinumab might not appear to be more cost 
effective than Etanercept, but it may be recommended due to modest increase in 
QALYs and convenient dosage pattern of once in 12 weeks.
SENSORY SYSTEMS DISORDERS – Patient-Reported Outcomes Studies
PSS13
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OBJECTIVES: The Visual Function Questionnaire Utility Index (VFQ-UI) is a vision-
speciﬁc preference measure developed from the National Eye Institute Visual Function 
Questionnaire 25 (NEI VFQ-25). The objective of this analysis was to assess the 
validity and reliability of the VFQ-UI in individuals with age-related macular degen-
eration (AMD). METHODS: Post-hoc analysis using data collected from a multi-
center, randomized controlled trial of 138 individuals with AMD. The NEI VFQ-25, 
HUI, and EQ-5D were administered at baseline and day 1 visits. The NEI VFQ-25 
dataset was used to calculate utility values using the VFQ-UI algorithm. Validity was 
assessed using convergent validity with HUI2, HUI3 and visual acuity and discrimi-
nant validity with the EQ-5D and known groups of visual acuity. Reliability was 
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assessed using Cronbach’s alpha and intra-class correlation. RESULTS: The mean age 
was 76.3 (8.9) years, majority of the subjects were female (55.1%), residing in the 
United States (77.5%) and Caucasian (92.8%). The mean utility value calculated with 
the VFQ-UI was 0.68 (0.11), compared to the EQ-5D: 0.88 (0.12), HUI2: 0.81 (0.13), 
and HUI3: 0.73 (0.22). The VFQ-UI is associated with HUI2 (r = 0.22, p < 0.05) but 
not signiﬁcantly associated with the EQ-5D or the HUI3. There was no signiﬁcance 
in the correlation between VFQ-UI and visual acuity in the study eye. The VFQ-UI 
varied by known groups using a combination of study and fellow eye visual acuity; 
the more impaired visual acuity the lower the utility value (more disability in visual 
functioning). Internal consistency reliability for the VFQ-UI was 0.76 and the intra-
class correlation was 0.84. CONCLUSIONS: Utility values calculated from the 
VFQ-UI demonstrated greater visual functioning impairment compared to the HUI 
and EQ-5D. The VFQ-UI showed good convergent validity with the HUI2, good 
discriminant validity with visual acuity known groups and good internal consistency 
and test-retest reliability in individuals with AMD.
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OBJECTIVES: The Eyelash Satisfaction Questionnaire (ESQ), a static measure, has 
been previously validated for the assessment of eyelash-speciﬁc patient-reported out-
comes (PROs) in subjects receiving a therapeutic treatment for hypotrichosis of eye-
lashes. The current study aimed to validate a similar questionnaire, the Eyelash 
Satisfaction Follow-up Questionnaire (ESFQ), a 39-item dynamic measure designed 
speciﬁcally to self-assess eyelash-speciﬁc PROs. METHODS: The ESFQ was initially 
examined in a 909-person validation sample consisting of online respondents. Conﬁr-
matory factor analysis (CFA) was initially used to test the measurement structure of 
the questionnaire. Item- and scale-level psychometric properties such as item-total 
correlations, internal consistency, and convergent and discriminant validities were 
reviewed. The ESFQ was then used in a clinical population receiving bimatoprost 
ophthalmic solution 0.03%, a product that improves eyelash prominence, during a 
16-week randomized, controlled, masked, clinical trial. RESULTS: Initial CFA results 
revealed a “good ﬁt” based on hypothesized similarity with the factor structure identi-
ﬁed in the ESQ. A model using 9 indicators (3 per factor), similar to the structure of 
the ESQ, was chosen as the optimal method. The ﬁnal model showed good internal 
consistency along with convergent and discriminant validities. However, the alpha-
removed statistic for the length, fullness, and overall satisfaction (LFOS) construct 
showed a signiﬁcant increase in scale consistency with the removal of item 8 (Com-
pared to your ﬁrst visit, overall, how satisﬁed are you with your eyelashes now?). 
Despite this, the model structure was retained to better facilitate comparisons between 
the ESQ and ESFQ and to provide sufﬁcient measures to properly evaluate the con-
struct. CONCLUSIONS: The 9-item ESFQ appears to be a valid measure to assess 
changes in eyelash-speciﬁc PROs. The factor structure showed near equivalence with 
the ESQ. Future research will involve further validation of the ESFQ in response to 
variations in hypotrichosis etiologies and clinical treatment paradigms.
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OBJECTIVES: Our objective was to compare the PRO endpoints recommended by 
the EMEA note for guidance on the clinical investigation of medicinal products 
indicated for the treatment of psoriasis (CHMP/EWP/2454/02) published in Novem-
ber 2004, with those used for the approval of medicinal products for psoriasis. 
METHODS: The EMEA website was searched to identify all medicinal products 
approved speciﬁcally for psoriasis since 1995. PROlabels was searched to identify 
the products with a PRO labeling claim. RESULTS: The EMEA guidance speciﬁes 
that “Patient-assessed drug efﬁcacy may be a secondary or tertiary endpoint in 
pivotal clinical trials. These measures correspond both to efﬁcacy evaluated by 
patients and to health-related quality of life (HRQL) scales validated in dermatol-
ogy”. The guidance quotes simple measures such as symptom improvement, tolerabil-
ity, cosmetic acceptability, ease of use, patient’s assessment of global improvement 
and more complex measures, such as the patient’s assessment of PASI, the Dermatol-
ogy Life Quality Index (DLQI), Dermatology Quality Life Scales (DQOLS), Skindex, 
Psoriasis Disability Index (PDI), and Psoriasis Life Stress Inventory (PLSI). Three 
products were retrieved; two approved before the publication of the guidance (2003, 
2004) and one after (2009). Methotrexate, cyclosporine and corticoids were not 
included for their lack of speciﬁcity. All three products had a PRO labeling claim. 
Improvement in the DLQI was used as a secondary endpoint in all products and 
quoted on the label. Itch was measured for 2 products (2004, 2009) by patient’s 
symptom measures and included on the label. Two products (2003, 2009) used the 
SF-36. CONCLUSIONS: There is a close adherence to the guidance concerning the 
choice of PRO endpoints. However, comparison of the dates of the guidance pub-
lication and of the products’ approval suggest that the guidance has only endorsed 
an existing practice in the choice of study endpoints for the evaluation of medicines 
indicated for psoriasis.
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OBJECTIVES: To assess the long-term impact of ustekinumab(UST) on quality of life 
(QoL) among patients responding to therapy at wk40. METHODS: In PHOENIX 1 
psoriasis patients were randomized to UST45 mg (n = 255), UST90 mg(n = 256), or 
placebo(n = 255). Placebo patients crossed over to receive UST45 mg or 90 mg at 
wk12. At wk40, UST PASI75 responders were re-randomized to continue the same 
dose of UST q12 wks or be withdrawn from treatment.After losing 50% of the 
improvement gained while on UST, patients withdrawn from treatment re-initiated 
UST at the same dose previously received.The DLQI assessed skin disease-speciﬁc QoL 
(lower scores indicating better QoL) through 3 yrs;change of >= 5 points was deﬁned 
as a clinically meaningful change and a score of 0/1 was deﬁned as no negative effect 
on patient’s life. RESULTS: 162 patients were re-randomized to UST at wk40 (n = 
77,45 mg; n = 85,90 mg); 320 patients were withdrawn from UST at wk40 (n = 
141,45 mg; n = 179,90 mg). Among patients re-randomized to UST, mean change 
from baseline in DLQI score for the 45 mg and 90 mg groups [mean(SD)] was: 
−9.1(7.0) and −10.0(6.1) at wk76 and −8.6(6.9) and −9.7(6.2) at Year3, respectively.
Among patients withdrawn, mean change from baseline in DLQI score for the 
UST45 mg and 90 mg groups [mean(SD)] was: −1.4(5.8) and −4.2(4.7) at wk76 and 
0.9(2.2) and −2.8(0.9) at Year3, respectively. At wk76 and Year3, 64.0% and 74.7%, 
and 64.6% and 65.4% of patients in the 45 mg and 90 mg groups,respectively,achieved 
a DLQI score of 0/1; at wks76 and Year3, 10.9% and 19.2%, and 3.1% and 13.9%, 
of patients withdrawn from 45 mg and 90 mg, respectively, achieved these results. In 
those re-randomized to UST, the proportion of patients in the 45 mg and 90 mg 
groups who experienced a ≥5 point improvement in DLQI was 73.3% and 78.5% at 
wk76, and 70.8% and 78.2% at Year3; in the withdrawal group, 19.6% and 20.9%, 
and 0.78% and 1.3%, of patients from 45 mg and 90 mg, respectively, achieved this 
result. CONCLUSIONS: Clinically meaningful QoL improvements are sustained 
through Year3 among patients responding at wk40 who continued to receive UST 
q12wks.
PSS17
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OBJECTIVES: To evaluate the effect of adalimumab on health-related quality of life 
and patient-reported outcome (PRO) measures, including depression and health utility 
in patients with active plaque psoriasis. METHODS: PRIDE (A Canadian Open-Label 
Access PRogram to Evaluate the Safety and the Effectiveness of Adalimumab When 
Added to InaDEquate Therapy for the Treatment of Psoriasis) was an open-label, 
multicenter, Phase IIIb study in Canada. Patients with active moderate to severe plaque 
psoriasis who failed to respond to, or were intolerant of, prior therapies (photother-
apy, cyclosporine, methotrexate, and/or oral retinoids) received adalimumab (80 mg) 
at Week 0 followed by adalimumab (40 mg) every other week starting at Week 1. 
Changes in the Dermatology Life Quality Index (DLQI), Beck Depression Inventory-II 
(BDI) and EQ-5D at baseline, Week 16 and Week 24 were evaluated. RESULTS: A 
total of 203 patients (male, 61%; mean age, 46 years; mean PASI score, 20) were 
enrolled at 26 sites. At baseline, mean DLQI, BDI and EQ-5D were 12.9, 9.3, and 
0.79, respectively. At Week 16, the mean DLQI score had improved to 2.9 (change = 
10.0; p < 0.0001); the BDI was reduced to 5.2 (change = 4.2; p < 0.0001), and the 
EQ-5D had improved to 0.89 (change = 0.10; p < 0.0001). A 16-week results were 
sustained to 24-weeks, and all outcomes showed statistically signiﬁcant improvements 
from baseline. Improvements were even greater in patients with a baseline DLQI score 
>10. CONCLUSIONS: Adalimumab treatment was associated with statistically sig-
niﬁcant improvements in PROs of psoriasis patients in Canada, including depression. 
The results of this open-label study were consistent with outcomes observed in ran-
domized placebo controlled clinical trials of adalimumab, conﬁrming that adalimumab 
has a substantial impact on patient health-related quality of life.
